酒石酸卡巴拉汀
酒石酸卡巴拉汀结构式
|
常用名 | 酒石酸卡巴拉汀 | 英文名 | Rivastigmine (tartrate) |
|---|---|---|---|---|
| CAS号 | 129101-54-8 | 分子量 | 400.423 | |
| 密度 | N/A | 沸点 | 316.2ºC at 760 mmHg | |
| 分子式 | C18H28N2O8 | 熔点 | 123-1250C | |
| MSDS | 中文版 | 闪点 | 145ºC |
|
[Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Minerva Med. 105(2) , 167-74, (2014) Vascular dementia (VaD) is defined as a loss of cognitive function resulting from ischemic, hypoperfusive, or hemorrhagic brain lesions due to cerebrovascular disease or cardiovascular pathology. The main types of VaD are: Small Vessel Disease Dementia (sVAD)... |
|
|
Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.
Int. J. Geriatr. Psychiatry 28(12) , 1312-7, (2013) A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim of this study was to assess the potential influence of ACh... |
|
|
Rivastigmine for vascular cognitive impairment.
Cochrane Database Syst. Rev. 5 , CD004744, (2013) Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification ... |
|
|
Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.
J. Am. Geriatr. Soc. 61(7) , 1170-4, (2013) To highlight the utility of using an effect size analysis to communicate the effectiveness of treatment interventions.Secondary analysis.Previously published systematic review on cholinesterase inhibitors (ChEIs) in Alzheimer's disease.Individuals with mild t... |
|
|
Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.
Clin. Interv. Aging 8 , 1007-14, (2013) Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. ... |
|
|
Cholinergic symptoms with low serum cholinesterase from therapeutic cholinesterase inhibitor toxicity.
Am. J. Emerg. Med. 32(7) , 815.e3-4, (2014) Although cholinesterase inhibitors have been frequently used in the treatment of Alzheimer disease, its effects on serum cholinesterase concentrations have been rarely described. We described significant depression of serum cholinesterase levels due to cholin... |
|
|
Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia.
J. Pak. Med. Assoc. 62(7) , 677-80, (2012) To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine.Total 56 patients aged 50-75 years, suffering ... |
|
|
Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Drugs Today (Barc) 43(6) , 349-59, (2007) Parkinson's disease is associated with dementia in about 40% of cases, and in time up to 80% of patients will develop dementia. This dementia is characterized by deficits in attention, executive function and memory. While, as in Alzheimer's disease, cholinerg... |
|
|
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Medicina (B. Aires.) 73(3) , 213-23, (2013) Cognitive impairment and dementia treatment costs are significant for health systems. According to national and international guidelines, recommended drugs for treatment of dementias are cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and mem... |
|
|
Pharmacological treatment for memory disorder in multiple sclerosis.
Cochrane Database Syst. Rev. 12 , CD008876, (2013) This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10).Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegen... |